Drappatz, Jan

AZD2171, a Pan-VEGF Receptor Tyrosine Kinase Inhibitor, Normalizes Tumor Vasculature and Alleviates Edema in Glioblastoma Patients

Batchelor, T. T., Sorensen, A. G., di Tomaso, E., Zhang, W.-T., Duda, D. G., Cohen, K. S., Kozak, K. R., Cahill, D. P., Chen, P.-J., Zhu, M., et al. (2007) · Cancer Cell

Angiogenesis and VEGF in CancerGlioma Diagnosis and Treatment

Cited by 1,769

Phase II Study of Cediranib, an Oral Pan–Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent Glioblastoma

Batchelor, T. T., Duda, D. G., di Tomaso, E., Ancukiewicz, M., Plotkin, S. R., Gerstner, E., Eichler, A. F., Drappatz, J., Hochberg, F. H., Benner, T., et al. (2010) · Journal of Clinical Oncology

Glioma Diagnosis and TreatmentAngiogenesis and VEGF in Cancer

Cited by 520

Novel anti-angiogenic therapies for malignant gliomas

Norden, A. D., Drappatz, J., & Wen, P. Y. (2008) · The Lancet Neurology

Angiogenesis and VEGF in CancerGlioma Diagnosis and Treatment

Cited by 246

Phase I Study of GRN1005 in Recurrent Malignant Glioma

Drappatz, J., Brenner, A., Wong, E. T., Eichler, A., Schiff, D., Groves, M. D., Mikkelsen, T., Rosenfeld, S., Sarantopoulos, J., Meyers, C. A., et al. (2013) · Clinical Cancer Research

Glioma Diagnosis and TreatmentNanoparticle-Based Drug Delivery

Cited by 190